{"product_id":"edit-vrio-analysis","title":"Editas Medicine, Inc. (EDIT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking sustainable competitive advantage is the ultimate goal, and our deep-dive VRIO analysis of Editas Medicine, Inc. (EDIT) reveals precisely where its core strengths lie - assessing the Value, Rarity, Inimitability, and Organization of its key resources, as summarized by \u0026amp;O4\u0026amp;. Discover the critical factors driving Editas Medicine, Inc. (EDIT)'s market position and what it means for its future success by reading the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEditas Medicine, Inc. (EDIT) - VRIO Analysis: Exclusive Licensing of Foundational CRISPR IP (Cas9 \u0026amp; Cas12a)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core intellectual property moat for Editas Medicine, Inc. (EDIT) - the exclusive rights to foundational CRISPR technology. This isn't just academic; it directly impacts their ability to generate revenue and defend their pipeline. Honestly, in this space, IP is everything.\u003c\/p\u003e\n\n\u003ch\u003eExclusive Licensing of Foundational CRISPR IP (Cas9 \u0026amp; Cas12a)\u003c\/h\u003e\n\n\u003cp\u003eEditas Medicine, Inc. is the exclusive licensee for the Broad Institute’s Cas12a patent estate and the Broad Institute\/Harvard University’s Cas9 patent estates specifically for developing human medicines. This licensing structure is what allows them to build their in vivo therapies and, crucially, to sub-license the foundational tools to partners.\u003c\/p\u003e\n\n\u003ch\u003eValue: Enabling Medicine and Generating Cash\u003c\/h\u003e\n\n\u003cp\u003eThe value is clear: these licenses let the company develop human medicines using the two primary CRISPR systems, Cas9 and Cas12a. This translates directly into dollars. For instance, collaboration and other R\u0026amp;D revenues hit \u003cstrong\u003e$4.7 million\u003c\/strong\u003e in the first quarter of fiscal year 2025, up from $1.1 million the year prior, partly due to recognizing deferred revenue from a partner deal wrapping up. Plus, Q2 2025 collaboration revenue was \u003cstrong\u003e$3.6 million\u003c\/strong\u003e. This IP is definitely a cash generator, even if the core business is still burning cash, with a net loss of \u003cstrong\u003e$53.2 million\u003c\/strong\u003e in Q2 2025.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Uniqueness in the Sector\u003c\/h\u003e\n\n\u003cp\u003eThe exclusivity of the license to the Broad Institute's Cas12a estate and the Broad\/Harvard Cas9 estates for human medicines is quite rare in the gene editing sector. While many companies use CRISPR, holding the exclusive license for these foundational tools in the human therapeutic space creates a significant barrier to entry for competitors looking to use the exact same core technology for their own in vivo programs. It’s a rare piece of real estate in biotech.\u003c\/p\u003e\n\n\u003ch\u003eImitability: Contractual Lock-in vs. Scientific Pursuit\u003c\/h\u003e\n\n\u003cp\u003eImitability is high because these rights are contractually locked in with the licensors. However, the underlying science is being pursued by others globally, which means the technology itself isn't perfectly inimitable, only the right to use the licensed patents is. The ongoing patent interference proceedings - where a May 2025 Federal Circuit decision remanded the Cas9 case back to the PTAB - show that the legal landscape is still being fought over, even if the Cas12a patents are unaffected. The strength of this barrier hinges on the final legal outcomes.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Active Monetization and Runway Extension\u003c\/h\u003e\n\n\u003cp\u003eOrganizationally, Editas Medicine is strong here because they actively monetize this IP. The agreement with Vertex Pharmaceuticals, for example, provided an upfront payment and annual licensing fees, which, along with other cash management, helps extend the company’s cash runway into the third quarter of 2027. As of September 30, 2025, they held \u003cstrong\u003e$165.6 million\u003c\/strong\u003e in cash, cash equivalents, and marketable securities, partly supported by these licensing streams. They are structured to use this IP to fund their pipeline development.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how this IP translates to the VRIO assessment:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eSupporting Data\/Context (FY 2025)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eGenerated \u003cstrong\u003e$4.7M\u003c\/strong\u003e (Q1 2025) and \u003cstrong\u003e$3.6M\u003c\/strong\u003e (Q2 2025) in collaboration revenue.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eExclusive license to Broad\/Harvard Cas9 \u0026amp; Cas12a estates for human medicines.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eDifficult (High)\u003c\/td\u003e\n    \u003ctd\u003eContractually locked in, though underlying science is globally pursued; patent disputes ongoing.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eActively monetized (e.g., Vertex deal) to extend cash runway into Q3 2027.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eCompetitive Advantage: Sustained Potential\u003c\/h\u003e\n\n\u003cp\u003eGiven the positive assessment across the first four dimensions, the competitive advantage is currently scored as \u003cstrong\u003eSustained\u003c\/strong\u003e. This is provided the underlying patent disputes remain favorable to the Broad Institute’s position or are otherwise managed through licensing structures that benefit Editas Medicine. What this estimate hides is the risk that a major adverse patent ruling could force renegotiation or devalue the exclusivity, but for now, the contractual rights are a powerful shield.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft the Q4 2025 cash flow projection incorporating expected milestone payments by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEditas Medicine, Inc. (EDIT) - VRIO Analysis: Proprietary In Vivo Gene Upregulation Strategy\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eProprietary In Vivo Gene Upregulation Strategy\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nOffers a differentiated approach to gene editing by amplifying existing protein expression, potentially creating durable, one-time treatments for diseases with high unmet need.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nThe strategy targets HBG1\/2 promoters to upregulate fetal hemoglobin (HbF) for sickle cell disease and beta thalassemia.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThis specific strategy, focusing on upregulation rather than just knockout\/insertion, is less common than standard editing approaches.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate; while the concept is known, the specific, optimized execution is proprietary and backed by preclinical data.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nExclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003e\u0026lt;\u0026gt;\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh, as this strategy is central to their current pipeline focus, with development candidates selected by mid-2025.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\nPlanned declaration of two in vivo editing development candidates, one in HSCs and one in liver, by mid-2025.\n\u003c\/li\u003e\n\u003cli\u003e\nLead in vivo development candidate, EDIT-401, was selected in September 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nIND\/CTA submission for the lead program is targeted by mid-2026.\n\u003c\/li\u003e\n\u003cli\u003e\nHuman proof-of-concept is targeted by the end of 2026.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eFinancial Position Supporting Organization:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Date\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$221.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Expectation\u003c\/td\u003e\n\u003ctd\u003eInto the second quarter of 2027\u003c\/td\u003e\n\u003ctd\u003eBased on cash as of December 31, 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$237.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the full year ended December 31, 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003e\u0026lt;\u0026gt;\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary; it’s a strong differentiator now, but competitors could develop similar functional upregulation methods.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003ePreclinical Efficacy Data Supporting Strategy:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\/Target\u003c\/th\u003e\n\u003cth\u003eModel\u003c\/th\u003e\n\u003cth\u003eEditing\/Reduction Achieved\u003c\/th\u003e\n\u003cth\u003eThreshold\/Comparison\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBG1\/2 Upregulation (HbF)\u003c\/td\u003e\n\u003ctd\u003eNHP HSCs\u003c\/td\u003e\n\u003ctd\u003eUp to 47% editing\u003c\/td\u003e\n\u003ctd\u003eExceeded therapeutic threshold of ≥25%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBG1\/2 Upregulation (HbF)\u003c\/td\u003e\n\u003ctd\u003eHumanized Mice HSCs\u003c\/td\u003e\n\u003ctd\u003e48% editing\u003c\/td\u003e\n\u003ctd\u003eExceeded therapeutic threshold of ≥25%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLDLR Upregulation (EDIT-401)\u003c\/td\u003e\n\u003ctd\u003eNHP Liver\u003c\/td\u003e\n\u003ctd\u003e≥90% mean reduction of LDL-C\u003c\/td\u003e\n\u003ctd\u003eStandard of care: 40%-60% mean reduction.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLDLR Upregulation (EDIT-401)\u003c\/td\u003e\n\u003ctd\u003eNHP Liver\u003c\/td\u003e\n\u003ctd\u003e≥6-fold mean increase in LDLR protein\u003c\/td\u003e\n\u003ctd\u003eAchieved with ~10-40% functional editing of LDLR alleles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eEditas Medicine, Inc. (EDIT) - VRIO Analysis: Proprietary Targeted Lipid Nanoparticle (tLNP) Delivery Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eProprietary Targeted Lipid Nanoparticle (tLNP) Delivery Platform\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eEssential for their in vivo focus, enabling the delivery of gene editing cargo directly to hard-to-reach cells like hematopoietic stem cells (HSCs) with a single dose. A single intravenous administration of the tLNP resulted in mean on-target editing levels in the HBG1\/2 promoter region of up to 58% in HSCs in non-human primates (NHPs) at five months post-dose. This level exceeds the predicted editing threshold of ≥25% required for therapeutic benefit.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTarget Cell\/Model\u003c\/th\u003e\n\u003cth\u003eEditing Target\u003c\/th\u003e\n\u003cth\u003eObserved Editing Level\u003c\/th\u003e\n\u003cth\u003eDose Frequency\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHSCs in NHPs\u003c\/td\u003e\n\u003ctd\u003eHBG1\/2 Promoter\u003c\/td\u003e\n\u003ctd\u003e58% mean at five months\u003c\/td\u003e\n\u003ctd\u003eSingle intravenous dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term HSCs in Humanized Mice\u003c\/td\u003e\n\u003ctd\u003eHBG1\/2 Promoter\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003ctd\u003eSingle dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eYes, a proprietary, validated in vivo delivery system that works across multiple cell types (HSCs, liver) is a significant asset. The platform has demonstrated in vivo proof of concept for editing in both hematopoietic stem cells (HSCs) and liver cells in non-human primates.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eHigh; developing effective, non-viral in vivo delivery is a major hurdle that competitors struggle to replicate quickly. The proprietary tLNP formulation demonstrates significant de-targeting of the liver in contrast to standard LNPs in NHPs.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; they are actively presenting data validating the tLNP's in vivo capabilities in non-human primates (NHPs). The company is on track to declare two in vivo editing development candidates, one in HSCs and one in liver, in mid-2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperational runway extends into the second quarter of 2027.\u003c\/li\u003e\n\u003cli\u003eAnticipated 2025 milestones include presenting further in vivo HSC data and presenting in vivo data in one liver indication.\u003c\/li\u003e\n\u003cli\u003eStrategic priorities through 2027 include achieving human in vivo proof of concept in HSC editing for the treatment of sickle cell disease and beta thalassemia.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained, as delivery technology often creates a deeper moat than the nuclease itself in the in vivo space. The clinically validated strategy for editing HBG1\/2 promoters to upregulate fetal hemoglobin (HbF) is supported by the in vivo delivery success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEditas Medicine, Inc. (EDIT) - VRIO Analysis: In Vivo Pipeline Focus (HSC \u0026amp; Liver Candidates)\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the in vivo gene editing programs targeting Hematopoietic Stem Cells (HSC) and Liver tissue, which represent the company's current strategic priority.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eFuture commercial potential is anchored by the planned declaration of two development candidates (HSC and liver) by mid-2025. The lead in vivo candidate, EDIT-401, targets LDL cholesterol reduction, with preclinical data showing a $\\ge 90\\%$ reduction in mean LDL-C in non-human primates within 48 hours of a single dose. The company is on track to submit an Investigational New Drug (IND) or Clinical Trial Application (CTA) for EDIT-401 by mid-2026. The operational runway, supported by $178.5 million in cash, cash equivalents, and marketable securities as of June 30, 2025, is projected into the second quarter of 2027.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe existence of two distinct, advanced in vivo programs is a strong position, though not unique in the broader gene editing field. Preclinical proof of concept for HSPC editing was achieved with an editing level of $29\\%$ in humanized mice using a prior strategy.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eLow, as the specific targets and data packages, including the proprietary targeted Lipid Nanoparticle (tLNP) delivery system for extrahepatic tissue, are unique to Editas Medicine. The specific preclinical results, such as achieving $\\ge 90\\%$ LDL-C reduction with only $\\sim 10-40\\%$ functional editing of LDLR alleles in the liver, represent a unique data package.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eHigh; the entire company structure and resource allocation shifted to support this in vivo focus.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses for the three months ended June 30, 2025, were $16.2 million.\u003c\/li\u003e\n\u003cli\u003eThe company is on track to establish and disclose an additional target cell type\/tissue by the end of 2025.\u003c\/li\u003e\n\u003cli\u003eThe company discontinued the reni-cel program to focus resources on the lead EDIT-401 program.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary; the advantage is in the progress made, but it hinges on successful IND filing by mid-2026 and achieving human proof-of-concept by the end of 2026.\u003c\/p\u003e\n\u003cp\u003eKey preclinical data supporting the in vivo pipeline:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram\/Target\u003c\/td\u003e\n\u003ctd\u003ePreclinical Model\u003c\/td\u003e\n\u003ctd\u003eKey Efficacy Metric\u003c\/td\u003e\n\u003ctd\u003eResult\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDIT-401 (Liver\/LDL-C)\u003c\/td\u003e\n\u003ctd\u003eNon-Human Primate (NHP)\u003c\/td\u003e\n\u003ctd\u003eMean LDL-C Reduction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\ge 90\\%$\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDIT-401 (Liver\/LDL-C)\u003c\/td\u003e\n\u003ctd\u003eNHP\u003c\/td\u003e\n\u003ctd\u003eLDLR Protein Increase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\ge 6$-fold\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDIT-401 (Liver\/LDL-C)\u003c\/td\u003e\n\u003ctd\u003eNHP\u003c\/td\u003e\n\u003ctd\u003eFunctional Editing Required\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$\\sim 10-40\\%$\u003c\/strong\u003e of alleles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHSC Editing (Previous)\u003c\/td\u003e\n\u003ctd\u003eHumanized Mouse\u003c\/td\u003e\n\u003ctd\u003eHSPC Editing Level\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29\\%$\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eEditas Medicine, Inc. (EDIT) - VRIO Analysis: Collaboration with Bristol Myers Squibb\n\u003c\/h2\u003e\n\n\u003cp\u003e\nThe following provides statistical and financial data points relevant to the VRIO analysis of the Editas Medicine and Bristol Myers Squibb collaboration.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eCollaboration with Bristol Myers Squibb\u003c\/strong\u003e\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eValue\u003c\/strong\u003e: Provides external validation, non-dilutive funding via milestone payments (like the one triggered in Q2 2025), and access to clinical\/commercial expertise in cell therapy.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCollaboration and other research and development revenues for the three months ended June 30, 2025: \u003cstrong\u003e$3.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities as of June 30, 2025: \u003cstrong\u003e$178.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; large pharma collaborations are common, but this one is tied to their ex vivo cell medicine work.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNumber of opted-into programs to date: \u003cstrong\u003e13\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNumber of gene targets involved: \u003cstrong\u003e11\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability\u003c\/strong\u003e: Low; the specific terms and history of the partnership are unique to Editas Medicine.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOriginal strategic research collaboration initiated in: \u003cstrong\u003e2015\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCurrent research agreement extension period: Through \u003cstrong\u003e2026\u003c\/strong\u003e, with options extending into \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; they successfully executed on a milestone within this agreement in the second quarter of 2025.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFirst IND\/CTA accepted for the CD19 HD Allo CAR T program in Q2 2025, triggering a milestone payment.\u003c\/li\u003e\n\u003cli\u003ePrograms currently in IND-enabling studies: \u003cstrong\u003e2\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrograms in late-stage discovery: \u003cstrong\u003e4\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; the value is realized through milestones, but the relationship itself is subject to renewal or termination.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperational runway expected into the second quarter of \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eReporting Period\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, \u0026amp; Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$178.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration Revenue Recognized\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Opted-In Programs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of May 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Agreement Expiration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExtended\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrograms in IND-Enabling Studies\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of May 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eEditas Medicine, Inc. (EDIT) - VRIO Analysis: Financial Runway into Q2 2027\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial Runway into Q2 2027\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides crucial time for R\u0026amp;D execution without immediate need for dilutive financing, which is vital given the high-burn nature of gene editing research. The Company expects its existing cash, cash equivalents, marketable securities, along with expected ATM proceeds and retained Vertex payments, to fund operating expenses and capital expenditure requirements into the \u003cstrong\u003ethird quarter of 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many clinical-stage biotechs face shorter runways, making this extended period a relative strength. The cash runway was maintained despite a net loss attributable to common stockholders of \u003cstrong\u003e$53.2 million\u003c\/strong\u003e for the three months ended June 30, 2025, and \u003cstrong\u003e$25.1 million\u003c\/strong\u003e for the three months ended September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a function of past financing, cost-cutting (like the reni-cel discontinuation), and partner payments. The discontinuation of the clinical development of the \u003cstrong\u003ereni-cel\u003c\/strong\u003e program initiated in December 2024 was a key factor in cost reduction.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; management explicitly tied cost-cutting measures to achieving this runway extension. The Company raised \u003cstrong\u003e$17.8 million\u003c\/strong\u003e of gross equity proceeds from its at-the-market (“ATM”) facility for the three months ended September 30, 2025, and expects to utilize \u003cstrong\u003e$17.3 million\u003c\/strong\u003e of proceeds from ATM sales after September 30, 2025, as part of the funding plan.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this is a depleting asset that must be replenished through future financing or partnerships. The cash, cash equivalents, and marketable securities balance decreased from \u003cstrong\u003e$269.9 million\u003c\/strong\u003e as of December 31, 2024, to \u003cstrong\u003e$165.6 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003eThe financial position and operational changes supporting the runway are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue as of June 30, 2025\u003c\/th\u003e\n\u003cth\u003eValue as of September 30, 2025\u003c\/th\u003e\n\u003cth\u003eComparison Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$178.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$165.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$269.9 million\u003c\/strong\u003e (Dec 31, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Attributable to Common Stockholders (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$53.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$67.6 million\u003c\/strong\u003e (Q2 2024) \/ \u003cstrong\u003e$62.1 million\u003c\/strong\u003e (Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Reni-cel Wind-down Costs\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$45.0 million to $55.0 million\u003c\/strong\u003e (Estimated as of Dec 31, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring\/Impairment Charges (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0\u003c\/strong\u003e (Q2 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe impact of cost-cutting on operating expenses for the three months ended June 30, 2025, compared to the same period in 2024, demonstrates organizational alignment with the runway goal:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and development expenses decreased by \u003cstrong\u003e$38.0 million\u003c\/strong\u003e to \u003cstrong\u003e$16.2 million\u003c\/strong\u003e (from \u003cstrong\u003e$54.2 million\u003c\/strong\u003e in Q2 2024).\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses decreased by \u003cstrong\u003e$5.3 million\u003c\/strong\u003e to \u003cstrong\u003e$12.9 million\u003c\/strong\u003e (from \u003cstrong\u003e$18.2 million\u003c\/strong\u003e in Q2 2024).\u003c\/li\u003e\n\u003cli\u003eCollaboration and other research and development revenues were \u003cstrong\u003e$3.58 million\u003c\/strong\u003e in Q2 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEditas Medicine, Inc. (EDIT) - VRIO Analysis: Dual Nuclease Capability (Cas9 and Cas12a)\n\u003c\/h2\u003e\n\u003cp\u003eThe dual nuclease capability leverages exclusive intellectual property rights across both the Cas9 and Cas12a platforms for human medicines.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eOffers flexibility to target a wider array of genetic mutations with different enzyme characteristics, potentially leading to more precise or effective edits for specific diseases.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate; Editas is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eModerate; competitors can license or develop their own nucleases, but the combination of licensed rights is specific.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh; demonstrated by the advancement of in vivo programs utilizing different systems, such as achieving proof of concept in the liver with \u003cstrong\u003eAsCas12a\u003c\/strong\u003e delivery by LNP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary; it provides optionality now, but the market may favor one nuclease over the other as data matures.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eSupporting Statistical and Financial Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEditas Medicine is the exclusive licensee of Broad Institute's \u003cstrong\u003eCas12a\u003c\/strong\u003e patent estate and Broad Institute and Harvard University's \u003cstrong\u003eCas9\u003c\/strong\u003e patent estates for human medicines.\u003c\/li\u003e\n\u003cli\u003eThe Company monetized a portion of its Cas9 license agreement with Vertex Pharmaceuticals, receiving an upfront cash payment of \u003cstrong\u003e$57 million\u003c\/strong\u003e from DRI Healthcare Trust.\u003c\/li\u003e\n\u003cli\u003eThe original Vertex Cas9 license involved an initial \u003cstrong\u003e$50 million\u003c\/strong\u003e upfront payment, with potential for a further \u003cstrong\u003e$50 million\u003c\/strong\u003e contingent payment and annual licensing fees ranging from \u003cstrong\u003e$5 million to $40 million\u003c\/strong\u003e per year.\u003c\/li\u003e\n\u003cli\u003eThe Company expects its cash, cash equivalents, and marketable securities, which stood at \u003cstrong\u003e$178.5 million\u003c\/strong\u003e as of June 30, 2025, to fund operations into the \u003cstrong\u003esecond quarter of 2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePreclinical data validation includes achieving proof of concept in non-human primates with \u003cstrong\u003eAsCas12a\u003c\/strong\u003e for liver editing.\u003c\/li\u003e\n\u003cli\u003eThe Company remains on track to declare an in vivo development candidate for its liver program in mid-2025 and file an IND by mid-2026, aiming for human proof-of-concept by year-end 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEditas Medicine, Inc. (EDIT) - VRIO Analysis: Preclinical Proof-of-Concept in Key Tissues (HSC\/Liver in NHPs)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e De-risks the core in vivo platform by showing functional editing in relevant animal models (NHPs), a critical step before human trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; achieving in vivo proof-of-concept in NHPs for HSC editing is a significant technical milestone few have reached.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; this is based on proprietary data and execution of complex preclinical studies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this data was a key driver for the company’s strategic pivot and confidence in 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage fades as competitors present their own compelling preclinical data.\u003c\/p\u003e\n\n\u003cp\u003eThe preclinical proof-of-concept data in Non-Human Primates (NHPs) for the in vivo platform demonstrated key efficacy metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTissue\/Program\u003c\/td\u003e\n\u003ctd\u003eModel\u003c\/td\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eObserved Value\u003c\/td\u003e\n\u003ctd\u003eThreshold\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHSC (HBG1\/2 Editing)\u003c\/td\u003e\n\u003ctd\u003eNHP\u003c\/td\u003e\n\u003ctd\u003eMean Editing at Five Months (Single Dose)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e58%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExceeded predicted therapeutic threshold of \u003cstrong\u003e≥25%\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHSC (HBG1\/2 Editing)\u003c\/td\u003e\n\u003ctd\u003eNHP\u003c\/td\u003e\n\u003ctd\u003eEditing Level (Initial Report)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e47%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSingle intravenous dose.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHSC (HBG1\/2 Editing)\u003c\/td\u003e\n\u003ctd\u003eHumanized Mice\u003c\/td\u003e\n\u003ctd\u003eEditing Level (Long-term HSCs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSingle dose; exceeded predicted threshold of \u003cstrong\u003e≥25%\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver Cells\u003c\/td\u003e\n\u003ctd\u003eNHP\u003c\/td\u003e\n\u003ctd\u003eProof of Concept\u003c\/td\u003e\n\u003ctd\u003eHigh Efficiency Gene Editing\u003c\/td\u003e\n\u003ctd\u003eFirst use of AsCas12a delivery by LNP.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe organizational confidence and strategic execution were supported by financial positioning and defined timelines:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnticipated 2025 milestones included declaring two in vivo development candidates, one in HSCs and one in liver.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, were \u003cstrong\u003e$165.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperational runway was extended into the \u003cstrong\u003ethird quarter of 2027\u003c\/strong\u003e as of November 2025.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the three months ended September 30, 2025, were \u003cstrong\u003e$19.8 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$47.6 million\u003c\/strong\u003e for the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eThe company was on track to submit an Investigational New Drug (IND) or Clinical Trial Application (CTA) for the lead in vivo program (EDIT-401, a liver-targeting program) by \u003cstrong\u003emid-2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEditas Medicine, Inc. (EDIT) - VRIO Analysis: Strategic Focus on In Vivo Medicine (Post-reni-cel Discontinuation)\n\u003c\/h2\u003e\n\u003ch\u003eStrategic Focus on In Vivo Medicine (Post-reni-cel Discontinuation)\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Concentrates limited capital and talent onto the area with the highest perceived long-term potential (in vivo editing), streamlining operations and reducing distraction from less promising assets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; many peers are also focusing on in vivo, but the decision to fully commit after discontinuing a clinical asset is a specific organizational choice.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; this is a strategic path, not a replicable resource, though the outcome (focus) can be copied.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company executed a major workforce reduction to align with this singular focus.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWorkforce reduction of approximately \u003cstrong\u003e65%\u003c\/strong\u003e (or \u003cstrong\u003e180\u003c\/strong\u003e positions, about \u003cstrong\u003etwo-thirds\u003c\/strong\u003e of the workforce) initiated in December 2024.\u003c\/li\u003e\n\u003cli\u003eDiscontinuation of development for renizgamglogene autogedtemcel (reni-cel).\u003c\/li\u003e\n\u003cli\u003eAim to demonstrate in-human, in vivo gene editing proof-of-concept data within \u003cstrong\u003etwo years\u003c\/strong\u003e from the December 2024 announcement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the market rewards focus, but only if the chosen path proves successful over the next few years.\u003c\/p\u003e\n\u003ch\u003eFinance: Key Metrics Supporting Strategic Focus\u003c\/h\u003e\n\u003cp\u003eThe company's financial position is being managed to support the in vivo pivot, with restructuring costs incurred from the ex vivo program wind-down.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended September 30, 2025 (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.54 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree months ended September 30, 2025 (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$165.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Extension\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eQ3 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on September 30, 2025 cash position and current plans\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring\/Impairment Charges YTD\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$66.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-to-date September 30, 2025, tied to ex vivo program wind-down\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe expected Q3 2025 partner revenue of \u003cstrong\u003e$7.5 million\u003c\/strong\u003e, primarily from a BMS milestone, contributed to the cash position supporting operations into \u003cstrong\u003eQ3 2027\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516155814037,"sku":"edit-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/edit-vrio-analysis.png?v=1740169044","url":"https:\/\/dcf-model.com\/fr\/products\/edit-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}